Evidence map›Paper›PMID 27328746›Full record

ArticleHIV medicine2017

High frequency of mitochondrial DNA mutations in HIV-infected treatment-experienced individuals.

M Li, Y Foli, Z Liu, G Wang, Y Hu, Q Lu, S Selvaraj, W Lam, E Paintsil

Abstract read
In one paragraph

Article in HIV medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Review
  15. Article
  16. Review
  17. Frailty in People Living with HIV.Current HIV/AIDS reports · 2020
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M LiDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
Y FoliDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
Z LiuDepartment of Pathology, Yale School of Medicine, New Haven, CT, USA.
G WangYale Center for Genome Analysis, Yale School of Medicine, West Haven, CT, USA.
Y HuSchool of Public Health, Yale University, New Haven, CT, USA.
Q LuSchool of Public Health, Yale University, New Haven, CT, USA.
S SelvarajDepartment of Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
W LamDepartment of Pharmacology, Yale School of Medicine, New Haven, CT, USA.
E PaintsilDepartment of Pediatrics, Yale School of Medicine, New Haven, CT, USA.

Funding

HIV Nucleoside Analogs Translational Studies: Resistance and MetabolismK08AI074404 · NIAID · YALE UNIVERSITY · PI PAINTSIL, ELIJAH · 2008 to 2012
$629k
NIAID NIH HHS K08 AI074404
6 · The paper itself

Abstract

objectivesWe recently observed a decrease in deoxyribonucleotide (dNTP) pools in HIV-infected individuals on antiretroviral therapy (ART). Alterations in dNTPs result in mutations in mitochondrial DNA (mtDNA) in cell culture and animal models. Therefore, we investigated whether ART is associated with mitochondrial genome sequence variation in peripheral blood mononuclear cells (PBMCs) of HIV-infected treatment-experienced individuals.

methodsIn this substudy of a case-control study, 71 participants were included: 22 'cases', who were HIV-infected treatment-experienced patients with mitochondrial toxicity, 25 HIV-infected treatment-experienced patients without mitochondrial toxicity, and 24 HIV-uninfected controls. Total DNA was extracted from PBMCs and purified polymerase chain reaction (PCR) products were subjected to third-generation sequencing using the PacBio Single Molecule Real-Time (SMRT) sequencing technology. The sequences were aligned against the revised Cambridge reference sequence for human mitochondrial DNA (NC_012920.1) for detection of variants.

resultsWe identified a total of 123 novel variants, 39 of them in the coding region. HIV-infected treatment-experienced patients with and without toxicity had significantly higher average numbers of mitochondrial variants per participant than HIV-uninfected controls. We observed a higher burden of mtDNA large-scale deletions in HIV-infected treatment-experienced patients with toxicity compared with HIV-uninfected controls (P = 0.02). The frequency of mtDNA molecules containing a common deletion (mt.δ4977) was higher in HIV-infected treatment-experienced patients with toxicity compared with HIV-uninfected controls (P = 0.06). There was no statistically significant difference in mtDNA variants between HIV-infected treatment-experienced patients with and without toxicity.

conclusionsThe frequency of mtDNA variants (mutations and large-scale deletions) was higher in HIV-infected treatment-experienced patients with or without ART-induced toxicity than in uninfected controls.

Indexed as

MutationAnti-Retroviral AgentsCase-Control StudiesDNADNA, MitochondrialHIV InfectionsHumansLeukocytes, MononuclearMiddle AgedPolymerase Chain ReactionSequence Analysis, DNAAnti-Retroviral AgentsDNADNA, MitochondrialAntiretroviral therapyHIVmitochondrial haplogroupsmitochondrial toxicitymutagensisperipheral blood mononuclear cells

Identifiers

PMID27328746
PMCPMC5132110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.